Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 46 Diseases   0 Trials   0 Trials   35 News 
  • ||||||||||  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax, Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
    POST-TRANSPLANT HBV VACCINE COMPLIANCE AND SEROPROTECTION IN THORACIC ORGAN TRANSPLANT RECIPIENTS () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_940;    
    We observed suboptimal post-transplant HBV vaccine compliance and poor vaccine-induced seroprotection in thoracic organ transplant recipients, regardless of the vaccine used. This study's findings emphasize the need to explore alternative post-transplant HBV vaccination strategies to improve both compliance and seroprotection.
  • ||||||||||  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
    Retrospective data, Journal, Compliance:  Hepatitis B Vaccine Compliance, Serologic Response, and Durability in Adult Thoracic Organ Transplant Recipients. (Pubmed Central) -  Sep 21, 2024   
    Although less than half of thoracic organ transplant candidates completed HBV vaccine series pretransplant, Heplisav-B provided a higher vaccine completion rate and seroprotection than the 3-dose Recombivax HB. Clinicians should also be aware of the increased loss of HBV seroprotection in thoracic organ transplant recipients with age
  • ||||||||||  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
    Hepatitis B Vaccine Compliance and Seroresponse in Adult Thoracic Organ Transplant Candidates (Poster Hall, Exhibit Hall A, Level 2) -  May 6, 2024 - Abstract #ATC2024ATC_2133;    
    Given these findings, means to improve vaccination compliance are needed and preference to the shorter administration completion of Heplisav can help, with improved seroconversion rates. Assessment of seroprotection after HBV vaccination should be prioritized during the pre-transplant period.
  • ||||||||||  Journal:  Adult immunization. (Pubmed Central) -  Oct 14, 2022   
    Assessment of seroprotection after HBV vaccination should be prioritized during the pre-transplant period. No abstract available
  • ||||||||||  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax, PreHevbrio (recombinant hepatitis B vaccine) / VBI Vaccines
    Journal:  A three-antigen hepatitis B vaccine (PreHevbrio). (Pubmed Central) -  May 18, 2022   
    No abstract available No abstract available
  • ||||||||||  Engerix-B (hepatitis B vaccine recombinant) / GSK, Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
    Clinical, Journal:  Hepatitis B Vaccination Response in Hemodialysis Patients: The Impact of Dialysis Shift. (Pubmed Central) -  Feb 1, 2022   
    In the context of end-stage kidney disease, early dialysis start is not a significant predictor of HB vaccination response. The association between objectively measured postvaccination sleep duration and seroconversion rate should be investigated.
  • ||||||||||  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
    Retrospective data, Journal:  Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV. (Pubmed Central) -  Oct 27, 2021   
    The association between objectively measured postvaccination sleep duration and seroconversion rate should be investigated. Heplisav-B® was highly effective in achieving immunity to HBV in PLWH who failed non-adjuvanted recombinant vaccines.
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    Trial completion:  PNEU-PED: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (clinicaltrials.gov) -  Jun 2, 2021   
    P3,  N=1720, Completed, 
    Heplisav-B® was highly effective in achieving immunity to HBV in PLWH who failed non-adjuvanted recombinant vaccines. Active, not recruiting --> Completed
  • ||||||||||  Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
    Trial primary completion date:  PNEU-PED: Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) (clinicaltrials.gov) -  Feb 24, 2020   
    P3,  N=1720, Active, not recruiting, 
    Additional research is needed to elucidate the impact these various practices have on patient outcomes and healthcare expenditure. Trial primary completion date: Dec 2020 --> May 2021
  • ||||||||||  Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
    New P1 trial:  Hepatitis B Vaccine in Seniors (clinicaltrials.gov) -  Nov 14, 2019   
    P1,  N=52, Completed, 
  • ||||||||||  Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
    Journal:  From Infancy and Beyond… Ensuring a lifetime of hepatitis B virus (HBV) vaccine-induced immunity. (Pubmed Central) -  Apr 30, 2019   
    This dosage has been shown in multiple long-term studies and meta-analyses to be associated with a lower primary response, decreased antibody persistence over time, and a reduced booster response 10 to 20 years following immunization. Ongoing surveillance of this and other HBV neonatally-vaccinated populations, particularly in low endemic regions, is necessary to understand the impact on long-term protection in order to ensure lifelong protection against hepatitis B infection.
  • ||||||||||  Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
    Trial completion:  Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers (clinicaltrials.gov) -  Apr 5, 2018   
    P=N/A,  N=10, Completed, 
    Ongoing surveillance of this and other HBV neonatally-vaccinated populations, particularly in low endemic regions, is necessary to understand the impact on long-term protection in order to ensure lifelong protection against hepatitis B infection. Active, not recruiting --> Completed
  • ||||||||||  RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine) / Merck (MSD), Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
    Trial primary completion date:  A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) (clinicaltrials.gov) -  Dec 26, 2017   
    P3,  N=2808, Completed, 
    Active, not recruiting --> Completed Trial primary completion date: Jul 2013 --> Dec 2012
  • ||||||||||  Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
    Enrollment closed, Trial primary completion date:  Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers (clinicaltrials.gov) -  Dec 19, 2014   
    P=N/A,  N=8, Active, not recruiting, 
    Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jun 2015
  • ||||||||||  RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine) / Merck (MSD), Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
    Trial completion:  A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) (clinicaltrials.gov) -  Aug 12, 2013   
    P3,  N=2808, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Jun 2015 Active, not recruiting --> Completed
  • ||||||||||  RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine) / Merck (MSD), Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
    Trial completion:  Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13 (clinicaltrials.gov) -  May 23, 2013   
    P3,  N=1473, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  HBVaxPro (hepatitis-B vaccine (rDNA)) / Merck (MSD), Sanofi, Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
    Trial completion:  Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) (clinicaltrials.gov) -  Nov 26, 2012   
    P3,  N=722, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed